The major U.S. stock indexes closed higher for the week, with the S & P 500 and Nasdaq Composite breaking multiweek losing streaks. Earnings drove the action, despite some less-than-ideal macroeconomic reports on economic growth and inflation. Meta Platforms ‘ report gave the market a bit of a scare Wednesday night, contributing to Thursday’s declines … Read more
CNBC’s Jim Cramer on Friday walked investors through next week on Wall Street. It’s a week jam-packed with notable events, including earnings from Apple, Amazon and Eli Lilly. He also advised investors to pay attention to Wednesday’s Federal Reserve meeting and Friday’s employment figures from the Department of Labor. “We have to run such a … Read more
A food delivery messenger carries a take out bag outside aSweetgreen in Manhattan on September 14, 2023. Jeenah Moon | The Washington Post | Getty Images A highly popular group of weight loss and diabetes drugs is decreasing some consumers’ appetites — and also how much they spend on food. Most people taking those medications, … Read more
Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S & P 500’s performance over the past three years. The study results released by Eli Lilly on Wednesday highlight the … Read more
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Most doses of Eli Lilly‘s highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according … Read more
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. The … Read more
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Markets wobbly: After a weak attempt … Read more
Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. But that might not be enough to stop its stock from climbing higher. Prescription data for multiple Eli Lilly drugs — especially type-2 diabetes treatment Trulicity — points to weaker trends in … Read more
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury, the regulator … Read more
CNBC’s Jim Cramer reviewed Tuesday’s market action, saying stocks that saw losses — like Nvidia and Eli Lilly — remain winners but had simply run too much. “The stocks that pulled back today have everything going for them, except that they’ve already run so much that they’ve become vulnerable,” he said. He underscored his belief … Read more
